register

News & Trends - Biotechnology

Aussie biotech to initiate early phase trial in autoimmune disease

Health Industry Hub | August 20, 2024 |

Biotech News: Australian biotech company Noxopharm is gearing up to embark on its first in-human trial of SOF-SKN, a drug candidate aimed at combating cutaneous lupus erythematosus (CLE), a challenging skin condition linked to the autoimmune disease lupus.

Scheduled for early 2025, the HERACLES (Harnessing Endogenous Regulators Against CLE Study) trial will unfold on home turf in Australia, strategically leveraging local expertise in lupus research and early-phase clinical trials. This decision also positions Noxopharm to maximise benefits from the R&D Tax Incentive scheme.

SOF-SKN represents a pioneering oligonucleotide TLR7/8 antagonist, potentially changing the treatment paradigm of CLE by targeting the disease at its core rather than merely managing symptoms.

Book your tickets now! FINALISTS revealed! WINNERS to be crowned at the Awards ceremony on 16th October.

Noxopharm CEO, Dr Gisela Mautner, emphasised the significance of this milestone, stating, “This trial marks the return of Noxopharm to the small group of ASX-listed Australian companies that have made it to the clinical trial stage. It is a major milestone that we have achieved in record time, and we are really pleased to be going back to the clinic with our first asset from the very promising Sofra platform.

“We have been methodical and thorough in our approach, and we will continue to comply with established and approved procedures of conducting clinical trials as we begin this important phase of the drug development journey. While there is still a lot of work ahead, we are pressing forward as rapidly as possible and in line with the strategy we have set out over the past 18 months.”

Anticipated safety readouts from the trial are expected to be available four to six weeks after dosing concludes, with comprehensive data analysis slated for late 2025.

Looking beyond CLE, Noxopharm views SOF-SKN as an initial stride in harnessing its Sofra platform’s vast potential across broader autoimmune disease landscapes, including rheumatoid arthritis. The platform’s appeal has already attracted international interest, resulting in strategic agreements with mid-sized to billion-dollar companies.

“At the big picture level, we very much see this as just the first chapter in developing the Sofra platform across larger markets. We will make decisions with these ambitions in mind while continuing to introduce the huge potential of the platform to external stakeholders,” Dr Mautner remarked.

The urgency for effective lupus treatments is stark; current options focus on symptom management without addressing the underlying disease. With lupus primarily afflicting young adults aged 15 to 45, and no cure available for skin lupus, ongoing symptomatic treatment poses a perpetual necessity, presenting a substantial commercial opportunity for innovative medicines.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Clinical and Laboratory Haematologist and Lead of the Molecular Haematology Service

Clinicians call for closer monitoring of patients post CAR T therapy

Health Industry Hub | February 17, 2025 |

Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]

More


News & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after ban

Next-gen surgical mesh to fill critical gap after regulatory ban

Health Industry Hub | February 17, 2025 |

Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]

More


News & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails

Contraceptive lawsuit against Bayer fails

Health Industry Hub | February 17, 2025 |

The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]

More


News & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse

Health Industry Hub | February 17, 2025 |

The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]

More


This content is copyright protected. Please subscribe to gain access.